3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
30
Burkitt Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Biphenotypic, Acute
6
Recurrence
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Down Syndrome
3
Waldenstrom Macroglobulinemia
2
Smoldering Multiple Myeloma
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Lung Neoplasms
2
Leukemia
2
Immunoglobulin Light-chain Amyloidosis
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Leukemia, Plasma Cell
1
Interventions
Cyclophosphamide
24
fludarabine
15
Rituximab
14
Specimen Handling
9
Magnetic Resonance Spectroscopy
8
Doxorubicin
7
pirtobrutinib
6
Vincristine
6
Prednisone
6
polatuzumab vedotin
5
obinutuzumab
5
Biopsy
5
zanubrutinib
4
glofitamab
4
Nivolumab
4
Etoposide
4
Dexamethasone
4
Bendamustine Hydrochloride
4
tazemetostat
3
tafasitamab
3
pembrolizumab
3
ibrutinib
3
fludarabine phosphate
3
acalabrutinib
3
Immunotherapy, Adoptive
3
venetoclax
2
pomalidomide
2
loncastuximab tesirine
2
etoposide phosphate
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Calcium Dobesilate
×
90 days
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled